| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mammography | 19 | 2022 | 79 | 4.740 |
Why?
|
| Breast Neoplasms | 17 | 2022 | 459 | 4.100 |
Why?
|
| Phantoms, Imaging | 18 | 2022 | 100 | 3.520 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 12 | 2019 | 58 | 2.700 |
Why?
|
| Radiographic Image Enhancement | 11 | 2021 | 28 | 2.550 |
Why?
|
| Image Interpretation, Computer-Assisted | 12 | 2018 | 107 | 1.970 |
Why?
|
| Cadmium Compounds | 4 | 2022 | 6 | 1.730 |
Why?
|
| X-Rays | 8 | 2022 | 31 | 1.650 |
Why?
|
| Algorithms | 18 | 2022 | 430 | 1.570 |
Why?
|
| Chromosomes, Human | 7 | 2013 | 32 | 1.560 |
Why?
|
| Image Processing, Computer-Assisted | 11 | 2022 | 251 | 1.550 |
Why?
|
| Quantum Dots | 2 | 2022 | 6 | 1.510 |
Why?
|
| Karyotyping | 5 | 2013 | 25 | 1.460 |
Why?
|
| Radiation Dosage | 5 | 2016 | 54 | 1.450 |
Why?
|
| Spectrometry, X-Ray Emission | 4 | 2018 | 12 | 1.440 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2021 | 474 | 1.420 |
Why?
|
| Metaphase | 6 | 2014 | 30 | 1.310 |
Why?
|
| Gold | 4 | 2015 | 130 | 1.290 |
Why?
|
| Breast | 4 | 2022 | 52 | 1.280 |
Why?
|
| High-Throughput Screening Assays | 3 | 2014 | 38 | 1.240 |
Why?
|
| Microscopy, Fluorescence | 4 | 2013 | 163 | 1.060 |
Why?
|
| Microscopy | 4 | 2022 | 38 | 1.050 |
Why?
|
| Endothelium, Vascular | 3 | 2014 | 325 | 1.050 |
Why?
|
| Pattern Recognition, Automated | 5 | 2015 | 32 | 0.960 |
Why?
|
| Metal Nanoparticles | 4 | 2015 | 130 | 0.950 |
Why?
|
| Proteasome Endopeptidase Complex | 4 | 2014 | 80 | 0.950 |
Why?
|
| Radiography | 5 | 2015 | 202 | 0.880 |
Why?
|
| Equipment Design | 10 | 2018 | 217 | 0.880 |
Why?
|
| Humans | 51 | 2022 | 28097 | 0.870 |
Why?
|
| Signal Processing, Computer-Assisted | 4 | 2018 | 69 | 0.850 |
Why?
|
| Reproducibility of Results | 12 | 2020 | 769 | 0.840 |
Why?
|
| Photons | 3 | 2022 | 27 | 0.820 |
Why?
|
| Sensitivity and Specificity | 10 | 2017 | 521 | 0.670 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2017 | 129 | 0.640 |
Why?
|
| Artifacts | 2 | 2012 | 50 | 0.640 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.640 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 53 | 0.640 |
Why?
|
| Inflammation | 3 | 2014 | 636 | 0.620 |
Why?
|
| Tellurium | 4 | 2022 | 6 | 0.600 |
Why?
|
| Neoplasms | 4 | 2021 | 809 | 0.590 |
Why?
|
| Lenses | 2 | 2022 | 12 | 0.590 |
Why?
|
| Microbubbles | 1 | 2017 | 5 | 0.570 |
Why?
|
| Ovarian Neoplasms | 6 | 2021 | 589 | 0.560 |
Why?
|
| Quality Control | 2 | 2016 | 21 | 0.550 |
Why?
|
| N-Acetylglucosaminyltransferases | 2 | 2014 | 16 | 0.550 |
Why?
|
| Lung | 1 | 2020 | 379 | 0.550 |
Why?
|
| Mammary Glands, Human | 1 | 2017 | 19 | 0.540 |
Why?
|
| Contrast Media | 1 | 2017 | 96 | 0.540 |
Why?
|
| Nitric Oxide | 2 | 2014 | 152 | 0.520 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2017 | 41 | 0.520 |
Why?
|
| X-Ray Microtomography | 1 | 2016 | 32 | 0.500 |
Why?
|
| Image Enhancement | 4 | 2015 | 58 | 0.500 |
Why?
|
| Chromosomes | 2 | 2022 | 59 | 0.490 |
Why?
|
| Female | 30 | 2022 | 15156 | 0.490 |
Why?
|
| Autophagy | 2 | 2014 | 73 | 0.490 |
Why?
|
| Animals | 24 | 2017 | 10423 | 0.490 |
Why?
|
| Adipose Tissue | 1 | 2017 | 183 | 0.490 |
Why?
|
| Radiology | 1 | 2015 | 20 | 0.470 |
Why?
|
| Absorption, Radiation | 1 | 2015 | 4 | 0.470 |
Why?
|
| Radiation Exposure | 1 | 2015 | 17 | 0.470 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 5 | 2014 | 65 | 0.430 |
Why?
|
| Radiometry | 1 | 2014 | 45 | 0.420 |
Why?
|
| Nanotechnology | 1 | 2014 | 68 | 0.420 |
Why?
|
| Hypoxia | 1 | 2014 | 89 | 0.420 |
Why?
|
| Chromosome Banding | 1 | 2013 | 6 | 0.410 |
Why?
|
| Molecular Imaging | 1 | 2013 | 35 | 0.410 |
Why?
|
| Pyruvaldehyde | 1 | 2012 | 1 | 0.400 |
Why?
|
| Immunotherapy | 5 | 2006 | 161 | 0.400 |
Why?
|
| Glycation End Products, Advanced | 1 | 2012 | 17 | 0.400 |
Why?
|
| Cytogenetic Analysis | 1 | 2012 | 10 | 0.400 |
Why?
|
| Equipment Failure Analysis | 5 | 2017 | 37 | 0.390 |
Why?
|
| Signal-To-Noise Ratio | 3 | 2018 | 16 | 0.390 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2012 | 56 | 0.390 |
Why?
|
| Chromosome Mapping | 1 | 2012 | 130 | 0.390 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2020 | 297 | 0.390 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2012 | 97 | 0.360 |
Why?
|
| Calibration | 3 | 2018 | 29 | 0.360 |
Why?
|
| Lasers | 2 | 2008 | 67 | 0.360 |
Why?
|
| Mammary Neoplasms, Experimental | 6 | 2011 | 48 | 0.350 |
Why?
|
| Laser Therapy | 6 | 2008 | 30 | 0.350 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 165 | 0.350 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 215 | 0.330 |
Why?
|
| Fourier Analysis | 3 | 2022 | 31 | 0.320 |
Why?
|
| Mice | 8 | 2016 | 4654 | 0.310 |
Why?
|
| Mice, Inbred C57BL | 5 | 2014 | 1576 | 0.310 |
Why?
|
| Artificial Intelligence | 2 | 2009 | 53 | 0.310 |
Why?
|
| Papanicolaou Test | 1 | 2009 | 24 | 0.310 |
Why?
|
| Vaginal Smears | 1 | 2009 | 44 | 0.310 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2009 | 75 | 0.310 |
Why?
|
| Machine Learning | 3 | 2018 | 84 | 0.290 |
Why?
|
| Optics and Photonics | 2 | 2005 | 23 | 0.280 |
Why?
|
| Oxidative Stress | 1 | 2012 | 668 | 0.280 |
Why?
|
| Retrospective Studies | 8 | 2022 | 2546 | 0.280 |
Why?
|
| Centromere | 1 | 2008 | 41 | 0.280 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2006 | 163 | 0.280 |
Why?
|
| Abdominal Fat | 2 | 2017 | 17 | 0.270 |
Why?
|
| Chitosan | 4 | 2013 | 34 | 0.270 |
Why?
|
| ROC Curve | 5 | 2019 | 144 | 0.250 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2022 | 41 | 0.250 |
Why?
|
| Photochemotherapy | 1 | 2006 | 42 | 0.240 |
Why?
|
| Pilot Projects | 2 | 2022 | 433 | 0.240 |
Why?
|
| Chickens | 3 | 2015 | 61 | 0.240 |
Why?
|
| Diagnostic Imaging | 2 | 2022 | 68 | 0.230 |
Why?
|
| Middle Aged | 10 | 2022 | 7138 | 0.220 |
Why?
|
| Subcutaneous Fat | 2 | 2021 | 17 | 0.210 |
Why?
|
| Intra-Abdominal Fat | 2 | 2021 | 21 | 0.210 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2015 | 819 | 0.210 |
Why?
|
| Animals, Laboratory | 1 | 2002 | 7 | 0.200 |
Why?
|
| Models, Biological | 2 | 2015 | 466 | 0.190 |
Why?
|
| Models, Statistical | 1 | 2002 | 128 | 0.190 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 474 | 0.180 |
Why?
|
| Area Under Curve | 3 | 2018 | 95 | 0.180 |
Why?
|
| Mastectomy | 1 | 2021 | 21 | 0.180 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 82 | 0.180 |
Why?
|
| Bevacizumab | 1 | 2021 | 103 | 0.170 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 42 | 0.170 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 17 | 0.170 |
Why?
|
| Male | 9 | 2014 | 13491 | 0.170 |
Why?
|
| Endothelial Cells | 2 | 2013 | 352 | 0.170 |
Why?
|
| Betacoronavirus | 1 | 2020 | 39 | 0.160 |
Why?
|
| Bone and Bones | 2 | 2015 | 75 | 0.160 |
Why?
|
| Prospective Studies | 1 | 2022 | 1248 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 186 | 0.150 |
Why?
|
| Disease Progression | 1 | 2020 | 473 | 0.150 |
Why?
|
| Time Factors | 2 | 2013 | 1592 | 0.150 |
Why?
|
| Feasibility Studies | 4 | 2016 | 193 | 0.150 |
Why?
|
| Aged | 9 | 2021 | 5400 | 0.150 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 405 | 0.140 |
Why?
|
| Tumor Burden | 1 | 2018 | 110 | 0.140 |
Why?
|
| Proteolysis | 2 | 2014 | 58 | 0.140 |
Why?
|
| Databases, Factual | 3 | 2019 | 253 | 0.140 |
Why?
|
| Miniaturization | 1 | 2017 | 10 | 0.140 |
Why?
|
| Cattle | 3 | 2013 | 388 | 0.130 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2008 | 58 | 0.130 |
Why?
|
| Linear Models | 2 | 2009 | 202 | 0.130 |
Why?
|
| Adjuvants, Immunologic | 3 | 2006 | 68 | 0.130 |
Why?
|
| Filtration | 1 | 2016 | 8 | 0.130 |
Why?
|
| Protons | 2 | 2013 | 54 | 0.120 |
Why?
|
| Chromatography, Affinity | 1 | 2015 | 32 | 0.120 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2015 | 32 | 0.120 |
Why?
|
| Silver | 1 | 2015 | 21 | 0.120 |
Why?
|
| Breast Diseases | 1 | 2015 | 7 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2015 | 36 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2018 | 612 | 0.120 |
Why?
|
| Plastics | 1 | 2015 | 6 | 0.120 |
Why?
|
| Fishes | 1 | 2015 | 32 | 0.120 |
Why?
|
| Radiation Protection | 1 | 2015 | 17 | 0.120 |
Why?
|
| Pulmonary Veins | 2 | 2006 | 108 | 0.120 |
Why?
|
| Antineoplastic Agents | 3 | 2016 | 679 | 0.120 |
Why?
|
| Sirtuin 1 | 1 | 2014 | 41 | 0.110 |
Why?
|
| Biomarkers | 1 | 2018 | 765 | 0.110 |
Why?
|
| beta-Transducin Repeat-Containing Proteins | 1 | 2014 | 3 | 0.110 |
Why?
|
| Enzyme Stability | 1 | 2014 | 31 | 0.110 |
Why?
|
| Cobalt | 1 | 2014 | 18 | 0.110 |
Why?
|
| Reactive Nitrogen Species | 1 | 2014 | 10 | 0.110 |
Why?
|
| Cell Line | 2 | 2014 | 696 | 0.110 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 70 | 0.110 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 60 | 0.110 |
Why?
|
| Transcription Factor RelA | 1 | 2013 | 21 | 0.110 |
Why?
|
| Acetylglucosamine | 1 | 2013 | 17 | 0.110 |
Why?
|
| Oligosaccharides | 1 | 2013 | 33 | 0.110 |
Why?
|
| Chitin | 2 | 2003 | 10 | 0.100 |
Why?
|
| Automation, Laboratory | 1 | 2013 | 4 | 0.100 |
Why?
|
| Mammary Glands, Animal | 1 | 2013 | 33 | 0.100 |
Why?
|
| Cells, Cultured | 2 | 2013 | 985 | 0.100 |
Why?
|
| Workflow | 1 | 2013 | 25 | 0.100 |
Why?
|
| Beclin-1 | 1 | 2012 | 4 | 0.100 |
Why?
|
| Task Performance and Analysis | 1 | 2013 | 43 | 0.100 |
Why?
|
| Cell Survival | 2 | 2012 | 409 | 0.100 |
Why?
|
| Blotting, Western | 2 | 2012 | 514 | 0.100 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2012 | 33 | 0.100 |
Why?
|
| Peroxynitrous Acid | 1 | 2012 | 7 | 0.100 |
Why?
|
| Computer Simulation | 1 | 2014 | 230 | 0.100 |
Why?
|
| Deoxycytidine | 2 | 2003 | 65 | 0.100 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2012 | 13 | 0.100 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 68 | 0.100 |
Why?
|
| Free Radical Scavengers | 1 | 2012 | 23 | 0.100 |
Why?
|
| Survival Analysis | 4 | 2021 | 288 | 0.100 |
Why?
|
| Ubiquitination | 1 | 2012 | 32 | 0.100 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 285 | 0.100 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2012 | 49 | 0.100 |
Why?
|
| Proteasome Inhibitors | 1 | 2012 | 26 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 133 | 0.100 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 632 | 0.100 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 281 | 0.100 |
Why?
|
| Tyrosine | 1 | 2012 | 92 | 0.100 |
Why?
|
| Green Fluorescent Proteins | 1 | 2012 | 101 | 0.100 |
Why?
|
| RNA Interference | 1 | 2012 | 137 | 0.100 |
Why?
|
| Sirolimus | 1 | 2012 | 76 | 0.090 |
Why?
|
| Low-Level Light Therapy | 1 | 2011 | 9 | 0.090 |
Why?
|
| Rats | 8 | 2011 | 1576 | 0.090 |
Why?
|
| Enzyme Activation | 1 | 2012 | 267 | 0.090 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 124 | 0.090 |
Why?
|
| NF-kappa B | 1 | 2012 | 191 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2021 | 2379 | 0.090 |
Why?
|
| Neoplasm Metastasis | 4 | 2005 | 162 | 0.090 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 507 | 0.090 |
Why?
|
| Cell Movement | 1 | 2012 | 373 | 0.090 |
Why?
|
| Blood Glucose | 1 | 2012 | 309 | 0.090 |
Why?
|
| Protein Binding | 1 | 2012 | 658 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2015 | 634 | 0.090 |
Why?
|
| Action Potentials | 3 | 2006 | 196 | 0.080 |
Why?
|
| Dogs | 3 | 2006 | 509 | 0.080 |
Why?
|
| Nanoparticles | 1 | 2014 | 287 | 0.080 |
Why?
|
| Models, Theoretical | 1 | 2011 | 134 | 0.080 |
Why?
|
| Breast Density | 2 | 2019 | 10 | 0.080 |
Why?
|
| Transducers | 1 | 2008 | 7 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2012 | 484 | 0.080 |
Why?
|
| Online Systems | 1 | 2008 | 11 | 0.080 |
Why?
|
| Computer-Aided Design | 1 | 2008 | 14 | 0.080 |
Why?
|
| Hyperthermia, Induced | 1 | 2008 | 30 | 0.070 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2008 | 33 | 0.070 |
Why?
|
| Decision Trees | 1 | 2008 | 7 | 0.070 |
Why?
|
| Models, Genetic | 1 | 2008 | 125 | 0.070 |
Why?
|
| Skin Temperature | 1 | 2007 | 5 | 0.070 |
Why?
|
| Leukemia | 1 | 2008 | 30 | 0.070 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2007 | 21 | 0.070 |
Why?
|
| Software | 1 | 2008 | 125 | 0.070 |
Why?
|
| Mitoguazone | 2 | 2003 | 2 | 0.070 |
Why?
|
| Sodium-Calcium Exchanger | 1 | 2006 | 20 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 237 | 0.060 |
Why?
|
| Hot Temperature | 1 | 2006 | 87 | 0.060 |
Why?
|
| Pyridinium Compounds | 1 | 2005 | 27 | 0.060 |
Why?
|
| Fluorescence | 1 | 2005 | 50 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 300 | 0.060 |
Why?
|
| Calcium | 1 | 2006 | 235 | 0.060 |
Why?
|
| Staining and Labeling | 1 | 2005 | 69 | 0.060 |
Why?
|
| Fluorescent Dyes | 1 | 2005 | 92 | 0.060 |
Why?
|
| Electric Stimulation | 1 | 2005 | 255 | 0.060 |
Why?
|
| Stochastic Processes | 1 | 2002 | 10 | 0.050 |
Why?
|
| Optical Fibers | 1 | 2002 | 5 | 0.050 |
Why?
|
| Supervised Machine Learning | 1 | 2022 | 8 | 0.050 |
Why?
|
| Fiber Optic Technology | 1 | 2002 | 14 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2003 | 409 | 0.050 |
Why?
|
| Unrelated Donors | 1 | 2022 | 1 | 0.050 |
Why?
|
| Siblings | 1 | 2022 | 23 | 0.050 |
Why?
|
| Fetal Blood | 1 | 2022 | 39 | 0.050 |
Why?
|
| Adult | 3 | 2021 | 7740 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 2021 | 0.050 |
Why?
|
| Atrial Fibrillation | 1 | 2005 | 402 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 356 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 31 | 0.040 |
Why?
|
| Adiposity | 1 | 2021 | 94 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 125 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2020 | 103 | 0.040 |
Why?
|
| Rats, Wistar | 2 | 2011 | 151 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2021 | 417 | 0.040 |
Why?
|
| Support Vector Machine | 1 | 2019 | 21 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2002 | 277 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2018 | 24 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2018 | 125 | 0.040 |
Why?
|
| Abdomen | 1 | 2017 | 41 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 126 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2016 | 15 | 0.030 |
Why?
|
| Cadmium | 1 | 2015 | 16 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2015 | 22 | 0.030 |
Why?
|
| Surface Properties | 1 | 2015 | 134 | 0.030 |
Why?
|
| Logistic Models | 1 | 2016 | 407 | 0.030 |
Why?
|
| Autophagy-Related Protein-1 Homolog | 1 | 2014 | 1 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2015 | 118 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2014 | 55 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2014 | 187 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2014 | 246 | 0.030 |
Why?
|
| Acylation | 1 | 2013 | 10 | 0.030 |
Why?
|
| Rats, Inbred WF | 2 | 2003 | 11 | 0.030 |
Why?
|
| Protein Transport | 1 | 2013 | 158 | 0.030 |
Why?
|
| Risk Factors | 1 | 2018 | 2081 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 157 | 0.020 |
Why?
|
| Survival Rate | 2 | 2003 | 430 | 0.020 |
Why?
|
| Diffusion | 1 | 2011 | 39 | 0.020 |
Why?
|
| Body Temperature | 1 | 2011 | 30 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2014 | 848 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2003 | 607 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 2733 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2003 | 1319 | 0.020 |
Why?
|
| Liver | 1 | 2011 | 440 | 0.020 |
Why?
|
| Thermography | 1 | 2007 | 2 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2007 | 62 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2013 | 1435 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2007 | 276 | 0.020 |
Why?
|
| Computers | 1 | 2006 | 30 | 0.020 |
Why?
|
| Acetylcholine | 1 | 2005 | 73 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 2005 | 79 | 0.010 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2005 | 96 | 0.010 |
Why?
|
| DNA | 1 | 2006 | 374 | 0.010 |
Why?
|
| Heart Atria | 1 | 2005 | 175 | 0.010 |
Why?
|
| Freeze Drying | 1 | 2003 | 10 | 0.010 |
Why?
|
| Adoptive Transfer | 1 | 2003 | 25 | 0.010 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2003 | 15 | 0.010 |
Why?
|
| Prognosis | 1 | 2006 | 803 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 2003 | 6 | 0.010 |
Why?
|
| Immune Sera | 1 | 2003 | 22 | 0.010 |
Why?
|
| Carcinogens | 1 | 2003 | 39 | 0.010 |
Why?
|
| Indocyanine Green | 1 | 2003 | 16 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2003 | 67 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2003 | 60 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2003 | 90 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2003 | 77 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2003 | 104 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 154 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 168 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 102 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2002 | 13 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 315 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 224 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 463 | 0.010 |
Why?
|
| Proteins | 1 | 2003 | 252 | 0.010 |
Why?
|
| Child | 1 | 2006 | 2242 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2003 | 1461 | 0.010 |
Why?
|